المؤلفون: Beddowes, E, Spicer, J, Chan, PY, Khadeir, R, Corbacho, JG, Repana, D, Steele, JP, Schmid, P, Szyszko, T, Cook, G, Diaz, M, Feng, X, Johnston, A, Thomson, J, Sheaff, M, Wu, B-W, Bomalaski, J, Pacey, S, Szlosarek, PW

المساهمون: Beddowes, Emma [0000-0001-7649-2863], Pacey, Simon [0000-0002-3303-7577], Apollo - University of Cambridge Repository

المصدر: Beddowes, E, Spicer, J, Chan, P Y, Khadeir, R, Garcia Corbacho, J, Repana, D, Steele, J P, Schmid, P, Szyszko, T, Cook, G, Diaz, M, Feng, X, Johnston, A, Thomason, J, Scheaff, M, Wu, B-W, Bomalaski, J, Pacey, S & Szlosarek, P W 2017, ' Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers ', Journal of Clinical Oncology, vol. 35, no. 16, pp. 1778-1785 . https://doi.org/10.1200/JCO.2016.71.3230

مصطلحات موضوعية: Male, Mesothelioma, Lung Neoplasms, Dose-Response Relationship, Drug, Hydrolases, Pleural Neoplasms, Mesothelioma, Malignant, Pemetrexed, Argininosuccinate Synthase, Middle Aged, Polyethylene Glycols, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Cisplatin, Aged

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16d3b5e67f628e85c2d09fcd2d9019a2
https://kclpure.kcl.ac.uk/ws/files/72158703/Phase_1_Dose_Escalation_Study_BEDDOWES_Publishedonline7April2017_GOLD_VoR_CC_BY_.pdf

المؤلفون: Wheatley DA; Royal Cornwall Hospital, Treliske, Truro, United Kingdom., Berardi R; AOU delle Marche, Università Politecnica delle Marche, Ancona, Italy., Climent Duran MA; Instituto Valenciano de Oncología, Valencia, Spain., Tomiak A; Kingston Health Sciences Centre, Kingston, Ontario, Canada., Greystoke AP; NU Cancer, Newcastle University, Newcastle upon Tyne, United Kingdom., Joshua AM; St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia., Arkenau HT; Sarah Cannon Research Institute, HCA Healthcare, London, United Kingdom., Géczi L; National Institute of Oncology, Budapest, Hungary., Corbacho JG; Clinic Institute of Hematological and Oncological Diseases, Hospital Clinic, Barcelona, Spain., Paz-Ares LG; Hospital Universitario 12 de Octubre, Madrid, Spain., Hussain SA; Weston Park Hospital, University of Sheffield, Sheffield, United Kingdom., Petruželka L; General University Hospital in Prague, Prague, Czech Republic., Delmonte A; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori,' Meldola, Italy., Chappey C; Pfizer, San Francisco, California., Masters JC; Pfizer, San Diego, California., Michelon E; Pfizer, New York, New York., Murphy DA; Pfizer, San Diego, California., Mwewa S; Pfizer, Paris, France., Cesari R; Pfizer, Milan, Italy., Doger de Spéville B; Fundación Jiménez Díaz University Hospital, Madrid, Spain.

المصدر: Cancer research communications [Cancer Res Commun] 2024 Jun 28; Vol. 4 (6), pp. 1609-1619.

نوع المنشور: Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II; Multicenter Study

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9918281580506676 Publication Model: Print Cited Medium: Internet ISSN: 2767-9764 (Electronic) Linking ISSN: 27679764 NLM ISO Abbreviation: Cancer Res Commun Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage , Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/pathology , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology, Humans ; Female ; Middle Aged ; Male ; Aged ; Carboplatin/administration & dosage ; Carboplatin/therapeutic use ; Carboplatin/adverse effects ; Gemcitabine ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/administration & dosage ; Deoxycytidine/therapeutic use ; Deoxycytidine/adverse effects ; Cisplatin/administration & dosage ; Cisplatin/therapeutic use ; Cisplatin/adverse effects ; Pemetrexed/therapeutic use ; Pemetrexed/administration & dosage ; Pemetrexed/adverse effects ; Adult ; Carcinoma, Transitional Cell/drug therapy ; Carcinoma, Transitional Cell/pathology ; Aged, 80 and over ; Urologic Neoplasms/drug therapy ; Urologic Neoplasms/pathology

المؤلفون: Prat A; SOLTI Cancer Research Group, Barcelona, Spain.; Medical Oncology Department, Hospital Clinic de Barcelona, Barcelona, Spain.; August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Medicine Department, University of Barcelona, Barcelona, Spain., Paz-Ares L; Hospital Universitario 12 de Octubre, Madrid, Spain.; CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), Instituto de Salud Carlos III, Madrid (Spain)., Juan M; August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Immunology Department, Immunotherapy Platforms, Hospital Clinic de Barcelona, Barcelona, Spain., Felip E; Vall d'Hebron Hospital Campus, Barcelona, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Garralda E; Vall d'Hebron Hospital Campus, Barcelona, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., González B; August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Pathology department Hospital Clinic de Barcelona, Barcelona, Spain., Arance A; Medical Oncology Department, Hospital Clinic de Barcelona, Barcelona, Spain., Martín-Liberal J; Catalan Institute of Oncology (ICO), Hospitalet, Barcelona, Spain., Gavilá J; SOLTI Cancer Research Group, Barcelona, Spain.; Instituto Valenciano de Oncología (IVO), Valencia, Spain., López-González A; Complejo Asistencial Universitario de León, Spain., Cejalvo JM; Hospital Clínico Universitario de Valencia, INCLIVA (Instituto de investigación sanitaria), Universidad Valencia, Spain., Izarzugaza Y; Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain., Amillano K; Hospital Universitari Sant Joan de Reus, Spain., Corbacho JG; SOLTI Cancer Research Group, Barcelona, Spain.; Medical Oncology Department, Hospital Clinic de Barcelona, Barcelona, Spain.; August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Saura C; SOLTI Cancer Research Group, Barcelona, Spain.; Vall d'Hebron Hospital Campus, Barcelona, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Racca F; IOB-Hospital Quironsalud Barcelona, Spain., Hierro C; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Badalona, Badalona-Applied Research Group in Oncology (B-ARGO), Germans Trias I Pujol Research Institute (IGTP); Badalona, Barcelona, Spain., Sanfeliu E; SOLTI Cancer Research Group, Barcelona, Spain.; Pathology department Hospital Clinic de Barcelona, Barcelona, Spain., Gonzalez X; SOLTI Cancer Research Group, Barcelona, Spain.; Institut Oncològic Dr. Rosell. Hospital Universitari General de Catalunya, Sant Cugat del Vallès, Spain., Canes J; SOLTI Cancer Research Group, Barcelona, Spain., Villacampa G; SOLTI Cancer Research Group, Barcelona, Spain.; Oncology Data Science, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Salvador F; SOLTI Cancer Research Group, Barcelona, Spain., Pascual T; SOLTI Cancer Research Group, Barcelona, Spain.; Medical Oncology Department, Hospital Clinic de Barcelona, Barcelona, Spain., Mesía R; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Badalona, Badalona-Applied Research Group in Oncology (B-ARGO), Germans Trias I Pujol Research Institute (IGTP); Badalona, Barcelona, Spain., Cervantes A; CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), Instituto de Salud Carlos III, Madrid (Spain).; Hospital Clínico Universitario de Valencia, INCLIVA (Instituto de investigación sanitaria), Universidad Valencia, Spain., Tabernero J; CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), Instituto de Salud Carlos III, Madrid (Spain).; Vall d'Hebron Hospital Campus, Barcelona, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; IOB-Hospital Quironsalud Barcelona, Spain.

المصدر: Future oncology (London, England) [Future Oncol] 2022 Oct 06. Date of Electronic Publication: 2022 Oct 06.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Future Medicine Ltd Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE

المؤلفون: Beddowes E; Emma Beddowes, Javier Garcia Corbacho, and Simon Pacey, University of Cambridge, Cambridge; James Spicer, Dimitra Repana, Teresa Szyszko, and Gary Cook, King's College London; Pui Ying Chan, Jeremy P. Steele, Peter Schmid, Michael Sheaff, and Peter W. Szlosarek, St Bartholomew's Hospital; Ramsay Khadeir, Peter Schmid, and Peter W. Szlosarek, Queen Mary University of London, London, United Kindgom; and Monica Diaz, Xiaoxing Feng, Amanda Johnston, Jim Thomson, Bor-Wen Wu, and John Bomalaski, Polaris Pharmaceuticals, San Diego, CA., Spicer J; Emma Beddowes, Javier Garcia Corbacho, and Simon Pacey, University of Cambridge, Cambridge; James Spicer, Dimitra Repana, Teresa Szyszko, and Gary Cook, King's College London; Pui Ying Chan, Jeremy P. Steele, Peter Schmid, Michael Sheaff, and Peter W. Szlosarek, St Bartholomew's Hospital; Ramsay Khadeir, Peter Schmid, and Peter W. Szlosarek, Queen Mary University of London, London, United Kindgom; and Monica Diaz, Xiaoxing Feng, Amanda Johnston, Jim Thomson, Bor-Wen Wu, and John Bomalaski, Polaris Pharmaceuticals, San Diego, CA., Chan PY; Emma Beddowes, Javier Garcia Corbacho, and Simon Pacey, University of Cambridge, Cambridge; James Spicer, Dimitra Repana, Teresa Szyszko, and Gary Cook, King's College London; Pui Ying Chan, Jeremy P. Steele, Peter Schmid, Michael Sheaff, and Peter W. Szlosarek, St Bartholomew's Hospital; Ramsay Khadeir, Peter Schmid, and Peter W. Szlosarek, Queen Mary University of London, London, United Kindgom; and Monica Diaz, Xiaoxing Feng, Amanda Johnston, Jim Thomson, Bor-Wen Wu, and John Bomalaski, Polaris Pharmaceuticals, San Diego, CA., Khadeir R; Emma Beddowes, Javier Garcia Corbacho, and Simon Pacey, University of Cambridge, Cambridge; James Spicer, Dimitra Repana, Teresa Szyszko, and Gary Cook, King's College London; Pui Ying Chan, Jeremy P. Steele, Peter Schmid, Michael Sheaff, and Peter W. Szlosarek, St Bartholomew's Hospital; Ramsay Khadeir, Peter Schmid, and Peter W. Szlosarek, Queen Mary University of London, London, United Kindgom; and Monica Diaz, Xiaoxing Feng, Amanda Johnston, Jim Thomson, Bor-Wen Wu, and John Bomalaski, Polaris Pharmaceuticals, San Diego, CA., Corbacho JG; Emma Beddowes, Javier Garcia Corbacho, and Simon Pacey, University of Cambridge, Cambridge; James Spicer, Dimitra Repana, Teresa Szyszko, and Gary Cook, King's College London; Pui Ying Chan, Jeremy P. Steele, Peter Schmid, Michael Sheaff, and Peter W. Szlosarek, St Bartholomew's Hospital; Ramsay Khadeir, Peter Schmid, and Peter W. Szlosarek, Queen Mary University of London, London, United Kindgom; and Monica Diaz, Xiaoxing Feng, Amanda Johnston, Jim Thomson, Bor-Wen Wu, and John Bomalaski, Polaris Pharmaceuticals, San Diego, CA., Repana D; Emma Beddowes, Javier Garcia Corbacho, and Simon Pacey, University of Cambridge, Cambridge; James Spicer, Dimitra Repana, Teresa Szyszko, and Gary Cook, King's College London; Pui Ying Chan, Jeremy P. Steele, Peter Schmid, Michael Sheaff, and Peter W. Szlosarek, St Bartholomew's Hospital; Ramsay Khadeir, Peter Schmid, and Peter W. Szlosarek, Queen Mary University of London, London, United Kindgom; and Monica Diaz, Xiaoxing Feng, Amanda Johnston, Jim Thomson, Bor-Wen Wu, and John Bomalaski, Polaris Pharmaceuticals, San Diego, CA., Steele JP; Emma Beddowes, Javier Garcia Corbacho, and Simon Pacey, University of Cambridge, Cambridge; James Spicer, Dimitra Repana, Teresa Szyszko, and Gary Cook, King's College London; Pui Ying Chan, Jeremy P. Steele, Peter Schmid, Michael Sheaff, and Peter W. Szlosarek, St Bartholomew's Hospital; Ramsay Khadeir, Peter Schmid, and Peter W. Szlosarek, Queen Mary University of London, London, United Kindgom; and Monica Diaz, Xiaoxing Feng, Amanda Johnston, Jim Thomson, Bor-Wen Wu, and John Bomalaski, Polaris Pharmaceuticals, San Diego, CA., Schmid P; Emma Beddowes, Javier Garcia Corbacho, and Simon Pacey, University of Cambridge, Cambridge; James Spicer, Dimitra Repana, Teresa Szyszko, and Gary Cook, King's College London; Pui Ying Chan, Jeremy P. Steele, Peter Schmid, Michael Sheaff, and Peter W. Szlosarek, St Bartholomew's Hospital; Ramsay Khadeir, Peter Schmid, and Peter W. Szlosarek, Queen Mary University of London, London, United Kindgom; and Monica Diaz, Xiaoxing Feng, Amanda Johnston, Jim Thomson, Bor-Wen Wu, and John Bomalaski, Polaris Pharmaceuticals, San Diego, CA., Szyszko T; Emma Beddowes, Javier Garcia Corbacho, and Simon Pacey, University of Cambridge, Cambridge; James Spicer, Dimitra Repana, Teresa Szyszko, and Gary Cook, King's College London; Pui Ying Chan, Jeremy P. Steele, Peter Schmid, Michael Sheaff, and Peter W. Szlosarek, St Bartholomew's Hospital; Ramsay Khadeir, Peter Schmid, and Peter W. Szlosarek, Queen Mary University of London, London, United Kindgom; and Monica Diaz, Xiaoxing Feng, Amanda Johnston, Jim Thomson, Bor-Wen Wu, and John Bomalaski, Polaris Pharmaceuticals, San Diego, CA., Cook G; Emma Beddowes, Javier Garcia Corbacho, and Simon Pacey, University of Cambridge, Cambridge; James Spicer, Dimitra Repana, Teresa Szyszko, and Gary Cook, King's College London; Pui Ying Chan, Jeremy P. Steele, Peter Schmid, Michael Sheaff, and Peter W. Szlosarek, St Bartholomew's Hospital; Ramsay Khadeir, Peter Schmid, and Peter W. Szlosarek, Queen Mary University of London, London, United Kindgom; and Monica Diaz, Xiaoxing Feng, Amanda Johnston, Jim Thomson, Bor-Wen Wu, and John Bomalaski, Polaris Pharmaceuticals, San Diego, CA., Diaz M; Emma Beddowes, Javier Garcia Corbacho, and Simon Pacey, University of Cambridge, Cambridge; James Spicer, Dimitra Repana, Teresa Szyszko, and Gary Cook, King's College London; Pui Ying Chan, Jeremy P. Steele, Peter Schmid, Michael Sheaff, and Peter W. Szlosarek, St Bartholomew's Hospital; Ramsay Khadeir, Peter Schmid, and Peter W. Szlosarek, Queen Mary University of London, London, United Kindgom; and Monica Diaz, Xiaoxing Feng, Amanda Johnston, Jim Thomson, Bor-Wen Wu, and John Bomalaski, Polaris Pharmaceuticals, San Diego, CA., Feng X; Emma Beddowes, Javier Garcia Corbacho, and Simon Pacey, University of Cambridge, Cambridge; James Spicer, Dimitra Repana, Teresa Szyszko, and Gary Cook, King's College London; Pui Ying Chan, Jeremy P. Steele, Peter Schmid, Michael Sheaff, and Peter W. Szlosarek, St Bartholomew's Hospital; Ramsay Khadeir, Peter Schmid, and Peter W. Szlosarek, Queen Mary University of London, London, United Kindgom; and Monica Diaz, Xiaoxing Feng, Amanda Johnston, Jim Thomson, Bor-Wen Wu, and John Bomalaski, Polaris Pharmaceuticals, San Diego, CA., Johnston A; Emma Beddowes, Javier Garcia Corbacho, and Simon Pacey, University of Cambridge, Cambridge; James Spicer, Dimitra Repana, Teresa Szyszko, and Gary Cook, King's College London; Pui Ying Chan, Jeremy P. Steele, Peter Schmid, Michael Sheaff, and Peter W. Szlosarek, St Bartholomew's Hospital; Ramsay Khadeir, Peter Schmid, and Peter W. Szlosarek, Queen Mary University of London, London, United Kindgom; and Monica Diaz, Xiaoxing Feng, Amanda Johnston, Jim Thomson, Bor-Wen Wu, and John Bomalaski, Polaris Pharmaceuticals, San Diego, CA., Thomson J; Emma Beddowes, Javier Garcia Corbacho, and Simon Pacey, University of Cambridge, Cambridge; James Spicer, Dimitra Repana, Teresa Szyszko, and Gary Cook, King's College London; Pui Ying Chan, Jeremy P. Steele, Peter Schmid, Michael Sheaff, and Peter W. Szlosarek, St Bartholomew's Hospital; Ramsay Khadeir, Peter Schmid, and Peter W. Szlosarek, Queen Mary University of London, London, United Kindgom; and Monica Diaz, Xiaoxing Feng, Amanda Johnston, Jim Thomson, Bor-Wen Wu, and John Bomalaski, Polaris Pharmaceuticals, San Diego, CA., Sheaff M; Emma Beddowes, Javier Garcia Corbacho, and Simon Pacey, University of Cambridge, Cambridge; James Spicer, Dimitra Repana, Teresa Szyszko, and Gary Cook, King's College London; Pui Ying Chan, Jeremy P. Steele, Peter Schmid, Michael Sheaff, and Peter W. Szlosarek, St Bartholomew's Hospital; Ramsay Khadeir, Peter Schmid, and Peter W. Szlosarek, Queen Mary University of London, London, United Kindgom; and Monica Diaz, Xiaoxing Feng, Amanda Johnston, Jim Thomson, Bor-Wen Wu, and John Bomalaski, Polaris Pharmaceuticals, San Diego, CA., Wu BW; Emma Beddowes, Javier Garcia Corbacho, and Simon Pacey, University of Cambridge, Cambridge; James Spicer, Dimitra Repana, Teresa Szyszko, and Gary Cook, King's College London; Pui Ying Chan, Jeremy P. Steele, Peter Schmid, Michael Sheaff, and Peter W. Szlosarek, St Bartholomew's Hospital; Ramsay Khadeir, Peter Schmid, and Peter W. Szlosarek, Queen Mary University of London, London, United Kindgom; and Monica Diaz, Xiaoxing Feng, Amanda Johnston, Jim Thomson, Bor-Wen Wu, and John Bomalaski, Polaris Pharmaceuticals, San Diego, CA., Bomalaski J; Emma Beddowes, Javier Garcia Corbacho, and Simon Pacey, University of Cambridge, Cambridge; James Spicer, Dimitra Repana, Teresa Szyszko, and Gary Cook, King's College London; Pui Ying Chan, Jeremy P. Steele, Peter Schmid, Michael Sheaff, and Peter W. Szlosarek, St Bartholomew's Hospital; Ramsay Khadeir, Peter Schmid, and Peter W. Szlosarek, Queen Mary University of London, London, United Kindgom; and Monica Diaz, Xiaoxing Feng, Amanda Johnston, Jim Thomson, Bor-Wen Wu, and John Bomalaski, Polaris Pharmaceuticals, San Diego, CA., Pacey S; Emma Beddowes, Javier Garcia Corbacho, and Simon Pacey, University of Cambridge, Cambridge; James Spicer, Dimitra Repana, Teresa Szyszko, and Gary Cook, King's College London; Pui Ying Chan, Jeremy P. Steele, Peter Schmid, Michael Sheaff, and Peter W. Szlosarek, St Bartholomew's Hospital; Ramsay Khadeir, Peter Schmid, and Peter W. Szlosarek, Queen Mary University of London, London, United Kindgom; and Monica Diaz, Xiaoxing Feng, Amanda Johnston, Jim Thomson, Bor-Wen Wu, and John Bomalaski, Polaris Pharmaceuticals, San Diego, CA., Szlosarek PW; Emma Beddowes, Javier Garcia Corbacho, and Simon Pacey, University of Cambridge, Cambridge; James Spicer, Dimitra Repana, Teresa Szyszko, and Gary Cook, King's College London; Pui Ying Chan, Jeremy P. Steele, Peter Schmid, Michael Sheaff, and Peter W. Szlosarek, St Bartholomew's Hospital; Ramsay Khadeir, Peter Schmid, and Peter W. Szlosarek, Queen Mary University of London, London, United Kindgom; and Monica Diaz, Xiaoxing Feng, Amanda Johnston, Jim Thomson, Bor-Wen Wu, and John Bomalaski, Polaris Pharmaceuticals, San Diego, CA.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2017 Jun 01; Vol. 35 (16), pp. 1778-1785. Date of Electronic Publication: 2017 Apr 07.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Multicenter Study

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*administration & dosage , Argininosuccinate Synthase/*deficiency , Carcinoma, Non-Small-Cell Lung/*drug therapy , Lung Neoplasms/*drug therapy , Mesothelioma/*drug therapy , Pleural Neoplasms/*drug therapy, Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carcinoma, Non-Small-Cell Lung/enzymology ; Cisplatin/administration & dosage ; Cisplatin/adverse effects ; Dose-Response Relationship, Drug ; Female ; Humans ; Hydrolases/administration & dosage ; Hydrolases/adverse effects ; Lung Neoplasms/enzymology ; Male ; Mesothelioma/enzymology ; Mesothelioma, Malignant ; Middle Aged ; Pemetrexed/administration & dosage ; Pemetrexed/adverse effects ; Pleural Neoplasms/enzymology ; Polyethylene Glycols/administration & dosage ; Polyethylene Glycols/adverse effects

المؤلفون: Spicer J; King's College London, Guy's Hospital, London, UK. Electronic address: james.spicer@kcl.ac.uk., Baird R; University of Cambridge, Department of Oncology, Cambridge, UK., Suder A; King's College London, Guy's Hospital, London, UK., Cresti N; Northern Centre for Cancer Care, Newcastle upon Tyne, UK., Corbacho JG; University of Cambridge, Department of Oncology, Cambridge, UK., Hogarth L; Northern Centre for Cancer Care, Newcastle upon Tyne, UK., Frenkel E; University of Texas Southwestern Medical Center, Dallas, TX, USA., Matsumoto S; Shionogi & Co. Ltd., Osaka, Japan., Kawabata I; Shionogi & Co. Ltd., Osaka, Japan., Donaldson K; Shionogi & Co. Ltd., Osaka, Japan., Posner J; Shionogi & Co. Ltd., Osaka, Japan., Sarker D; King's College London, Guy's Hospital, London, UK., Jodrell D; University of Cambridge, Department of Oncology, Cambridge, UK., Plummer R; Northern Centre for Cancer Care, Newcastle upon Tyne, UK.

المصدر: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2015 Jan; Vol. 51 (2), pp. 137-45. Date of Electronic Publication: 2014 Nov 27.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: ErbB Receptors/*antagonists & inhibitors , Neoplasms/*drug therapy , Quinazolines/*therapeutic use , Receptor, ErbB-2/*antagonists & inhibitors, Administration, Oral ; Adult ; Aged ; Area Under Curve ; Diarrhea/chemically induced ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Exanthema/chemically induced ; Fatigue/chemically induced ; Female ; Humans ; Male ; Metabolic Clearance Rate ; Middle Aged ; Neoplasms/metabolism ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/pharmacokinetics ; Protein Kinase Inhibitors/therapeutic use ; Quinazolines/adverse effects ; Quinazolines/pharmacokinetics ; Treatment Outcome ; Young Adult